Mahesh R Khairnar1, Umesh Wadgave1, Harish Jadhav2, Rahul Naik2. 1. Department of Public Health Dentistry, Bharati Vidyapeeth Deemed University Dental College & Hospital, Sangli, Maharashtra, India. 2. Department of Public Health Dentistry, A.C.P.M. Dental College and Hospital, Dhule, Maharashtra, India.
Abstract
INTRODUCTION: Oral cancer is considered to be a global pandemic. The study was conducted to assess the anti-cancer activities of Chlorhexidine (CHX) and Cranberry against oral cancer cell lines. MATERIAL AND METHODS: Anticancer activity of CHX and Cranberry extract (CE) was assessed against AW13516 (poorly to moderately differentiated squamous cell carcinoma of tongue) and KB (Nasopharyngeal carcinoma) using Sulforhodamine B (SRB) assay at the Advanced Centre for Treatment Research and Education in Cancer (ACTREC) Mumbai, India. Three dose related parameters GI50, TGI and LC50 were calculated for each drug. RESULTS: CE (80µg/ml) showed no anti-cancer property against AW13516 cell line; however it showed 70.6% growth inhibition against KB cell line. CHX demonstrated 80.15% & 95.7% of growth inhibition against AW13516 & KB cell line respectively. Both the drugs were less potential than positive control drug Adriamycin, as reflected by their GI50, TGI and LC50 values. CONCLUSION: CHX exhibited better anti-cancer properties than CE for both the oral cancer cell lines.
INTRODUCTION: Oral cancer is considered to be a global pandemic. The study was conducted to assess the anti-cancer activities of Chlorhexidine (CHX) and Cranberry against oral cancer cell lines. MATERIAL AND METHODS: Anticancer activity of CHX and Cranberry extract (CE) was assessed against AW13516 (poorly to moderately differentiated squamous cell carcinoma of tongue) and KB (Nasopharyngeal carcinoma) using Sulforhodamine B (SRB) assay at the Advanced Centre for Treatment Research and Education in Cancer (ACTREC) Mumbai, India. Three dose related parameters GI50, TGI and LC50 were calculated for each drug. RESULTS: CE (80µg/ml) showed no anti-cancer property against AW13516 cell line; however it showed 70.6% growth inhibition against KB cell line. CHX demonstrated 80.15% & 95.7% of growth inhibition against AW13516 & KB cell line respectively. Both the drugs were less potential than positive control drug Adriamycin, as reflected by their GI50, TGI and LC50 values. CONCLUSION: CHX exhibited better anti-cancer properties than CE for both the oral cancer cell lines.
Authors: Katherine M Weh; Yun Zhang; Connor L Howard; Amy B Howell; Jennifer L Clarke; Laura A Kresty Journal: Nutrients Date: 2022-02-24 Impact factor: 5.717